---
layout: default
title: Diclofenac Sodium
parent: 僅模型預測 (L5)
nav_order: 114
evidence_level: L5
indication_count: 0
---

# Diclofenac Sodium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The txgnn-pipeline skill covers training and deployment — not relevant here. Proceeding to generate the evaluation report from the Evidence Pack.

---

# Diclofenac Sodium: Repurposing Evaluation on Hold — No TxGNN Predictions Available

## One-Sentence Summary

Diclofenac Sodium is a well-established non-steroidal anti-inflammatory drug (NSAID), widely used for pain and inflammatory conditions worldwide.
However, **the TxGNN pipeline returned no predicted new indications** for this compound in the current evidence pack.
Without a repurposing target, clinical trial evidence, or literature linkage, a full evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not populated in evidence pack (DrugBank query returned 1 result but data was not mapped) |
| Predicted New Indication | Not available — `predicted_indications` array is empty |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction not generated; no supporting studies |
| New Zealand Market Status | Not marketed (0 authorisations on record) |
| Number of Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## New Zealand Market Information

No marketing authorisations were found for Diclofenac Sodium in the New Zealand regulatory database at the time of query (2026-03-29).

> **Note:** Diclofenac Sodium is a globally common NSAID with regulatory approval in many jurisdictions. A result of 0 licences is unexpected and likely reflects a data mapping issue in the pipeline rather than genuine absence from the market. Manual verification against Medsafe's online register is recommended before drawing conclusions.

---

## Safety Considerations

Safety data (key warnings, contraindications, and drug interactions) was not successfully mapped from the package insert or DDI database into this evidence pack.

> Please refer to the approved package insert and Medsafe product monograph for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack contains no TxGNN-predicted indications, no populated original indication text, no safety data, and no New Zealand licensing records — making it impossible to conduct a meaningful repurposing evaluation at this time.

**To proceed, the following is needed:**

- **Resolve pipeline mapping failure**: DrugBank and TFDA package insert queries both returned 1 result (`result_status: success`) but no data was written into `drug.original_moa`, `drug.drugbank_id`, or `taiwan_regulatory.licenses` — investigate the ETL step between raw query results and Evidence Pack serialisation
- **Re-run TxGNN prediction**: Confirm that Diclofenac Sodium is present in the knowledge graph node list; if the drug ID lookup failed silently, that would explain why `predicted_indications` is empty
- **Retrieve MOA from DrugBank**: The DrugBank query succeeded — extract mechanism of action (COX-1/COX-2 inhibition), categories, and approved indications from the cached result
- **Verify New Zealand market status manually**: Check the [Medsafe Databank](https://www.medsafe.govt.nz/regulatory/DbSearch.asp) directly; 0 licences for a common NSAID is anomalous
- **Re-run DDI query**: DDI returned `not_found` — consider querying under alternate drug names (e.g. "diclofenac", "voltaren") and verifying the drug name normalisation step
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

